Imaging Scans Track Heart Amyloidosis Disease Progression Over Time
Tests new heart scans in people with cardiac amyloidosis, repeated after one year.
Plain-language title generated from the registry record
Registry title: Multimodality Cardiac Imaging for Disease Progression in ATTR-CM
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- University Hospital ZurichZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dominik Benz
- Trial code
- NCT07112066
- Record updated
- 9 December 2025
- Original description
The goal of this clinical trial is to investigate whether new imaging techniques can help us to better understand the cardiac amyloidosis. The disease can be slowed down with various medications (e.g., tafamidis, acoramidis, or vutrisiran). However, treatment is not effective in all patients-in about one-third of cases, the disease continues to progress. So far, we know little about the exact causes of this and what biological changes occur in the heart muscle.Read full original descriptionShow less
Natural History of Cardiac Transthyretin Amyloidosis - Mechanistic Insights by Multimodality Imaging
The goal of this clinical trial is to investigate whether new imaging techniques can help us to better understand the cardiac amyloidosis. The disease can be slowed down with various medications (e.g., tafamidis, acoramidis, or vutrisiran). However, treatment is not effective in all patients-in about one-third of cases, the disease continues to progress. So far, we know little about the exact causes of this and what biological changes occur in the heart muscle.
The main question it aims to answer is:
Will new imaging techniques help us understand the course of the cardiac amyloidosis?
Participants will have additional examinations:
* At the beginning of the study: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination, questionnaires. * After a year: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination.
Time required:
* Heart ultrasound examination: 5-10 Minutes * Cardiac MRI: 2 hours * Cardiac PET: 2 hours * Questionnaires: 5-10 Minutes.
Inclusion: Participants with cardiac ATTR amyloidosis, as recently defined by multi-societal criteria, who are about to start tafamidis at the University Hospital Zurich.
Exclusion: Prior septal myocardial infarction; Any other disease-modifying therapy (e.g. patisiran); Ongoing supraventricular arrhythmia; Ventricular pacing.